

Ref: Syn/CS/SE/Reg 30/2021-22/Jan/04

## **Syngene International Limited**

Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India

T+91 80 6891 8000 F +91 80 6775 8808

National Stock Exchange of India Limited

CIN: L85110KA1993PLC01493 www.syngeneintl.com

January 13, 2022

To,

To, The Manager, The Manager, **BSE Limited** 

Corporate Relationship Department **Corporate Communication Department** Dalal Street, Mumbai - 400 001 Bandra (EAST), Mumbai - 400 051

**Scrip Code: 539268 Scrip Symbol: SYNGENE** 

#### **Subject: Intimation of Conference Call for Analysts and Investors**

Dear Sir/Madam,

Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the intimation for conference call for Analysts and Investors to be held on Thursday, January 20, 2022.

The above-mentioned information will also be available on website of the Company www.syngeneintl.com.

Request to kindly take this intimation on record.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED** 

Priyadarshini Mahapatra

**Company Secretary and Compliance Officer** 

## Syngene's Q3 FY2022 Results Conference Call

At 04:00 pm IST on 20th January 2022

The management team of Syngene International Limited ("Syngene") will organize a **conference call for Analysts and Investors on Thursday, 20<sup>th</sup> January at 04.00 pm IST** following the announcement of financial results for the quarter ended December 30, 2021.

The call will be initiated with a brief management discussion on the Q3 FY2022 performance followed by an interactive Question & Answer session. Mr. Jonathan Hunt - Syngene's Managing Director and Chief Executive Officer and other members of the senior management team will represent Syngene on the conference call.

Details of the conference call are as under:

Date:	Thursday, 20th January 2022
Time:	04:00 pm to 05:00 pm IST
Dial-in Numbers*	
Primary Number	+91 22 6280 1279 / +91 22 7115 8180
International Numbers	<ul> <li>USA – 18667462133 (Toll Free) /+13233868721 (Toll)</li> <li>UK – 08081011573 (Toll Free) /+442034785524 (Toll)</li> <li>Singapore – 8001012045 (Toll Free) /+6531575746 (Toll)</li> <li>Hong Kong – 800964448 (Toll Free) /+85230186877 (Toll)</li> <li>Australia – 1800053698 (Toll Free)</li> </ul>
Pre-registration Facility  (Diamond <i>Pass</i> ™ link)	Step 1: Pre-register <a href="here">here</a> . You will receive a passcode and a pin for the call on the registered email address.  Step 2: Dial into the call on the Conference Call date, enter the passcode
	& pin as prompted. You will be directly connected to the call

<sup>\*</sup>When using dial-in numbers mentioned please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time

# INVESTOR CONFERENCE CALL INVITE

Q3 FY 2021-22

Replay Facility	Dial in numbers: +91 22 7194 5757
	Playback ID: 69442
	The replay facility will be available from 20 <sup>th</sup> January 2022 till
	27 <sup>th</sup> January 2022
Conference Call Transcript	Will be available within 7 working days of the call on the corporate website: <a href="https://syngeneintl.com/">https://syngeneintl.com/</a>

# **About Syngene**

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Syngene's more than 4700 scientists offer both skills and the capacity to deliver great science, robust data management and IP security and quality manufacturing at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife, as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals including GSK and Merck KgaA. Syngene featured in the 2021 list of 'India's top 100 wealth creators' by Fortune India Magazine. For more details, visit <a href="https://syngeneintl.com/">https://syngeneintl.com/</a>

#### For further information, please contact:

Krishnan G
Syngene International

**2**: +91 8068919807

⊠:Krishnan.G@syngeneintl.com

**Disclaimer:** Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.